Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New HIV prevention pill shows promise in emergency rooms

NCT ID NCT04233372

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study tested a single pill called Delstrigo as a 28-day treatment to prevent HIV after a possible exposure. 399 adults who went to the emergency room for a potential HIV contact took the pill daily. The main goal was to see how many people finished the full 28-day course, and researchers also looked at side effects and reasons people stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Department and HIV & HCV Clinical Research Unit University Hospital Nantes

    Nantes, France

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

Conditions

Explore the condition pages connected to this study.